These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36621619)

  • 1. In situ vaccination followed by intramuscular poly-ICLC injections for the treatment of hepatocellular carcinoma in mouse models.
    Weng MT; Yang SF; Liu SY; Hsu YC; Wu MC; Chou HC; Chiou LL; Liang JD; Wang LF; Lee HS; Sheu JC
    Pharmacol Res; 2023 Feb; 188():106646. PubMed ID: 36621619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma.
    Vivas I; Iribarren K; Lozano T; Cano D; Lasarte-Cia A; Chocarro S; Gorraiz M; Sarobe P; Hervás-Stubbs S; Bilbao JI; Casares N; Lasarte JJ
    J Vasc Interv Radiol; 2019 Jul; 30(7):1098-1105. PubMed ID: 31101416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial.
    Salazar AM; Erlich RB; Mark A; Bhardwaj N; Herberman RB
    Cancer Immunol Res; 2014 Aug; 2(8):720-4. PubMed ID: 24801836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
    Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
    Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
    Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
    J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
    Kyi C; Roudko V; Sabado R; Saenger Y; Loging W; Mandeli J; Thin TH; Lehrer D; Donovan M; Posner M; Misiukiewicz K; Greenbaum B; Salazar A; Friedlander P; Bhardwaj N
    Clin Cancer Res; 2018 Oct; 24(20):4937-4948. PubMed ID: 29950349
    [No Abstract]   [Full Text] [Related]  

  • 7. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
    Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H
    Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
    Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
    Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.
    Ewel CH; Urba WJ; Kopp WC; Smith JW; Steis RG; Rossio JL; Longo DL; Jones MJ; Alvord WG; Pinsky CM
    Cancer Res; 1992 Jun; 52(11):3005-10. PubMed ID: 1591717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
    Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
    J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.
    Tsuji T; Sabbatini P; Jungbluth AA; Ritter E; Pan L; Ritter G; Ferran L; Spriggs D; Salazar AM; Gnjatic S
    Cancer Immunol Res; 2013 Nov; 1(5):340-50. PubMed ID: 24777970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-γ- and IL-17-producing CD8
    Ohkuri T; Kosaka A; Ikeura M; Salazar AM; Okada H
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34193567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain tumor immunotherapy with type-1 polarizing strategies.
    Okada H
    Ann N Y Acad Sci; 2009 Sep; 1174():18-23. PubMed ID: 19769732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response modifying activity in mice of polyinosinic: polycytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly-ICLC].
    Chirigos MA; Papademetriou V; Bartocci A; Read E; Levy HB
    Int J Immunopharmacol; 1981; 3(4):329-37. PubMed ID: 7333719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
    Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
    Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy.
    De Waele J; Verhezen T; van der Heijden S; Berneman ZN; Peeters M; Lardon F; Wouters A; Smits ELJM
    J Exp Clin Cancer Res; 2021 Jun; 40(1):213. PubMed ID: 34172082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.
    Rodríguez-Ruiz ME; Perez-Gracia JL; Rodríguez I; Alfaro C; Oñate C; Pérez G; Gil-Bazo I; Benito A; Inogés S; López-Diaz de Cerio A; Ponz-Sarvise M; Resano L; Berraondo P; Barbés B; Martin-Algarra S; Gúrpide A; Sanmamed MF; de Andrea C; Salazar AM; Melero I
    Ann Oncol; 2018 May; 29(5):1312-1319. PubMed ID: 29554212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-ICLC, a multi-functional immune modulator for treating cancer.
    Sultan H; Salazar AM; Celis E
    Semin Immunol; 2020 Jun; 49():101414. PubMed ID: 33011064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling.
    Gesuete R; Packard AE; Vartanian KB; Conrad VK; Stevens SL; Bahjat FR; Yang T; Stenzel-Poore MP
    J Neurochem; 2012 Nov; 123 Suppl 2(Suppl 2):75-85. PubMed ID: 23050645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.